GSK proposal for marketing Belimumab rejected by CDSCO panel
New Delhi: In a major setback to GlaxoSmithKline (GSK) Pharmaceuticals, the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) has rejected the drug maker's proposal to market the immunosuppressant medication Belimumab citing inadequate data.
Based on the results of the Global Clinical Trial (GCT) including sub set analysis on 66 Indian patients, the pharma major moved a proposal before the CDSCO committee for marketing authorization and local clinical trial waiver for Belimumab.
GlaxoSmithKline had announced in 2020 that the US Food and Drug Administration (FDA) had approved belimumab under brad name BENLYSTA for the treatment of adult patients with active lupus nephritis (LN) who are receiving standard therapy.
Lupus nephritis is a serious inflammation of the kidneys caused by systemic lupus erythematosus (SLE), the most common form of lupus, which can lead to end-stage kidney disease, requiring dialysis or a kidney transplant. The approval extends the current indication in the US to include both SLE and LN for both the intravenous and subcutaneous formulations, GSK had said in its release.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.